LJN452 + Placebo to LJN452
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Bile Acid Diarrhea
Conditions
Primary Bile Acid Diarrhea
Trial Timeline
Jan 16, 2016 → Jan 25, 2018
NCT ID
NCT02713243About LJN452 + Placebo to LJN452
LJN452 + Placebo to LJN452 is a phase 2 stage product being developed by Novartis for Primary Bile Acid Diarrhea. The current trial status is completed. This product is registered under clinical trial identifier NCT02713243. Target conditions include Primary Bile Acid Diarrhea.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02713243 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Bile Acid Diarrhea